Form 4: Ironwood Pharmaceuticals Director Julie McHugh Receives 45,000 Stock Grant

Ironwood Pharmaceuticals Inc. director Julie McHugh was granted 45,000 shares of Class A Common Stock as part of the company's non-employee director compensation policy.

Summary

• Julie McHugh, a Director of Ironwood Pharmaceuticals Inc. (IRWD), acquired 45,000 shares of Class A Common Stock.
• The transaction occurred on June 10, 2025.
• The shares were acquired at a price of $0, indicating a grant of restricted stock.
• This grant was made pursuant to the Second Amended and Restated Non-employee Director Compensation Policy, which became effective on January 1, 2024.
• Following this transaction, Julie McHugh directly beneficially owns 208,839 shares of Class A Common Stock.
• The restricted stock is set to vest in full on the date immediately preceding the annual meeting of stockholders for the next calendar year.

Sentiment

Score: 7

Explanation: The filing reports a routine stock grant to a director, which is a positive sign of alignment between management and shareholder interests, and is part of a standard compensation policy. It does not contain any negative or unexpected information.

Positives

• The grant of 45,000 shares to Director Julie McHugh aligns her interests with those of shareholders, as her compensation is tied to the company's equity performance.
• The transaction is part of a pre-existing, disclosed compensation policy (Second Amended and Restated Non-employee Director Compensation Policy, effective January 1, 2024), indicating structured corporate governance.

Future Outlook

The restricted stock granted to Director Julie McHugh is set to vest in full on the date immediately preceding the annual meeting of stockholders for the next calendar year, indicating a future milestone for this specific equity award.

Industry Context

This Form 4 filing reports a routine insider transaction, specifically a stock grant to a non-employee director, which is a common practice in the pharmaceutical industry and across publicly traded companies to align director interests with shareholders. It does not provide information on broader industry trends or competitive landscape.

Comparison to Industry Standards

• The grant of restricted stock to a non-employee director is a standard practice for public companies, including those in the pharmaceutical sector, to compensate board members and align their interests with long-term shareholder value. Specific comparable companies or projects are not mentioned in this filing.

Corporate Governance

Related Party Transactions

• The stock grant to Julie McHugh, a director, is a related party transaction, but it is a standard and disclosed form of compensation for non-employee directors.

Stakeholder Impact

• Shareholders: The grant aligns the director's interests with shareholders, potentially encouraging decisions that enhance long-term shareholder value.

Next Steps

• The restricted stock granted to Julie McHugh will vest in full on the date immediately preceding the annual meeting of stockholders for the next calendar year.

Key Dates

Recommendation

Keywords

Ironwood Pharmaceuticals, IRWD, Julie McHugh, Form 4, SEC filing, stock grant, restricted stock, director compensation, insider transaction, equity ownership